Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5382_Библиотеки_им_академика_М_И_Перельмана.pdf
144. Liang, S.H., Yokell, D.L., Jackson, R.N. etal. (2014). Microuidic continuous-ow
radiosynthesis of [
18
F]FPEB suitable for human PET imaging. Med. Chem. Commun. 5
(4): 432–435. https://doi.org/10.1039/C3MD00335C.
145. Stephenson, N.A., Holland, J.P., Kassenbrock, A. etal. (2015). Iodonium ylide-mediated radiouorination of
18
F-FPEB and validation for human use. J. Nucl. Med. 56 (3):
489–492. https://doi.org/10.2967/jnumed.114.151332.
146. Wang, L., Cheng, R., Fujinaga, M. etal. (2017). A facile radiolabeling of [
18
F]FDPA via
spirocyclic iodonium ylides: preliminary PET imaging studies in preclinical models of
neuroinammation. J. Med. Chem. 60 (12): 5222–5227. https://doi.org/10.1021/acs.
jmedchem.7b00432.
147. Kumata, K., Zhang, Y., Fujinaga, M. etal. (2018). [18F]DAA1106: automated radiosynthesis using spirocyclic iodonium ylide and preclinical evaluation for positron
emission tomography imaging of translocator protein (18 kDa). Bioorg. Med. Chem.
26 (17): 4817–4822. https://doi.org/10.1016/J.BMC.2018.08.017.
148. Graskemper, J.W., Wang, B., Qin, L. etal. (2011). Unprecedented directing group
ability of cyclophanes in arene uorinations with diaryliodonium salts. Org. Lett. 13
(12): 3158–3161. https://doi.org/10.1021/ol201080c.
149. Gao, Z., Lim, Y.H., Tredwell, M. etal. (2012). Metal-free oxidative uorination of
phenols with [
18
F]uoride. Angew. Chem. Int. Ed. 51 (27): 6733–6737. https://doi.
org/10.1002/anie.201201502.
150. Buckingham, F., Calderwood, S., Checa, B. etal. (2015). Oxidative uorination
of N-arylsulfonamides. J. Fluorine Chem. 180: 33–39. https://doi.org/10.1016/J.
JFLUCHEM.2015.07.030.
151. Ludwig, T., Ermert, J., and Coenen, H.H. (2002). 4-[
improved synthesis of n.c.a. 4-[
18
]uorophenol. Nucl. Med. Biol. 29 (2): 255–262.
18
]Fluoroarylalkylethers via an
https://doi.org/10.1016/S0969-8051(01)00302-X.
152. Stoll, T., Ermert, J., Oya, S. etal. (2004). Application of n.c.a. 4-[
diaryl ether syntheses of 2-(4-[
18
F]uorophenoxy)-benzylamines. J. Labelled Compd.
18
F]uorophenol in
Radiopharm. 47 (7): 443–455. https://doi.org/10.1002/jlcr.828.
153. Watson, D.A., Su, M., Teverovskiy, G. etal. (2009). Formation of ArF from LPdAr(F):
catalytic conversion of aryl triates to aryl uorides. Science 325 (5948): 1661–1664.
https://doi.org/10.1126/science.1178239.
154. Lee, H.G., Milner, P.J., and Buchwald, S.L. (2013). An improved catalyst system for
the Pd-catalyzed uorination of (hetero)aryl Triates. Org. Lett. 15 (21): 5602–5605.
https://doi.org/10.1021/ol402859k.
155. Cardinale, J., Ermert, J., Kügler, F. etal. (2012). Carrier-eect on palladium-catalyzed, nucleophilic
18
F-uorination of aryl triates. J. Labelled Compd. Radiopharm.
55 (12): 450–453. https://doi.org/10.1002/jlcr.2973.
156. Gouverneur, V. (2012). Flipping uoride’s reactivity. Nat. Chem. 4 (3): 152–154.
https://doi.org/10.1038/nchem.1280.
157. Kamlet, A.S., Neumann, C.N., Lee, E. etal. (2013). Application of palladium-medi-
18
ated
F-uorination to PET radiotracer development: overcoming hurdles to
translation. Woloschak GE, editor. PLoS One 8 (3): e59187. https://doi.org/10.1371/
journal.pone.0059187.
Chapter 08: Fluorine-18 Radiochemistry 285
158. Lee, E., Hooker, J.M., and Ritter, T. (2012). Nickel-mediated oxidative uorination
for PET with aqueous [
18
F] uoride. J. Am. Chem. Soc. 134 (42): 17456–17458. https://
doi.org/10.1021/ja3084797.
159. Lee, E., Hooker, J.M., and Ritter, T. (2012). Nickel-mediated oxidative uorination
for PET with aqueous [
18
F] uoride. J. Am. Chem. Soc. 134 (42): 17456–17458. https://
doi.org/10.1021/ja3084797.
160. Campbell, M.G. and Ritter, T. (2014). Late-stage uorination: from fundamentals to application. Org. Process Res. Dev. 18 (4): 474–480. https://doi.org/10.1021/
op400349g.
161. Strebl, M.G., Campbell, A.J., Zhao, W.-N. etal. (2017). HDAC6 brain mapping with
18
[
F]bavarostat enabled by a Ru-mediated deoxyuorination. ACS Cent. Sci. 3 (9):
1006–1014. https://doi.org/10.1021/acscentsci.7b00274.
162. Beyzavi, M.H., Mandal, D., Strebl, M.G. etal. (2017).
18
F-Deoxyuorination of phenols via Ru π-complexes. ACS Cent. Sci. 3 (9): 944–948. https://doi.org/10.1021/
acscentsci.7b00195.
163. Ichiishi, N., Canty, A.J., Yates, B.F. etal. (2013). Cu-catalyzed uorination of diaryliodonium salts with KF. Org. Lett. 15 (19): 5134–5137. https://doi.org/10.1021/
ol4025716.
164. Ye, Y. and Sanford, M.S. (2013). Mild copper-mediated uorination of aryl stannanes and aryl triuoroborates. J. Am. Chem. Soc. 135: 9. https://doi.org/10.1021/
ja400300g.
165. Tredwell, M., Preshlock, S.M., Taylor, N.J. etal. (2014). A general copper-mediated
nucleophilic
18
F uorination of arenes. Angew. Chem. Int. Ed. 53 (30): 7751–7755.
https://doi.org/10.1002/anie.201404436.
166. Wilson, T.C., Cailly, T., and Gouverneur, V. (2018). Boron reagents for divergent
radiochemistry. Chem. Soc. Rev. 47 (18): 6990–7005. https://doi.org/10.1039/
C8CS00499D.
167. Mossine, A.V., Brooks, A.F., Makaravage, K.J. etal. (2015). Synthesis of [
via the copper-mediated [
18
F]uorination of boronic acids. Org. Lett. 17 (23): 5780–
18
F]arenes
5783. https://doi.org/10.1021/acs.orglett.5b02875.
168. Makaravage, K.J., Brooks, A.F., Mossine, A.V. etal. (2016). Copper-mediated radiouorination of arylstannanes with [
18
F]K F. Org. Lett. 18 (20): 5440–5443. https://doi.
org/10.1021/acs.orglett.6b02911.
169. Taylor, N.J., Emer, E., Preshlock, S. etal. (2017). Derisking the cu-mediated
18
F-uorination of heterocyclic positron emission tomography radioligands. J. Am. Chem.
Soc. 139 (24): 8267–8276. https://doi.org/10.1021/jacs.7b03131.
170. Antuganov, D., Zykov, M., Timofeeva, K. etal. (2017). Eect of pyridine addition
on the eciency of copper-mediated radiouorination of aryl pinacol boronates.
ChemistrySelect 2 (26): 7909–7912. https://doi.org/10.1002/slct.201701628.
171. Antuganov, D., Zykov, M., Timofeev, V. etal. (2019). Copper-mediated radiouorination of aryl pinacolboronate esters: a straightforward protocol by using pyridinium sulfonates. Eur. J. Org. Chem. 2019 (5): 918–922. https://doi.org/10.1002/
ejoc.201801514.
286 Handbook of Radiopharmaceuticals
172. Zischler, J., Kolks, N., Modemann, D. etal. (2017). Alcohol-enhanced Cu-mediated
radiouorination. Chem. Eur. J. 23 (14): 3251–3256. https://doi.org/10.1002/
chem.201604633.
173. Zhang, X., Basuli, F., and Swenson, R.E. (2019). An azeotropic drying-free approach
for copper-mediated radiouorination without addition of base. J. Labelled Compd.
Radiopharm. 62 (3): 139–145. https://doi.org/10.1002/jlcr.3705.
174. Petersen, I.N., Villadsen, J., Hansen, H.D. etal. (2017).
iodonium ylides: application to the radiosynthesis of potential 5-HT
18
F-labelling of electron rich
receptor
2A
PET ligands. Org. Biomol. Chem. 15 (20): 4351–4358. https://doi.org/10.1039/
C7OB00628D.
175. Li, S., Cai, Z., Wu, X. etal. (2019). Synthesis and in vivo evaluation of a novel
PET radiotracer for imaging of synaptic vesicle glycoprotein 2A (SV2A) in nonhuman primates. ACS Chem. Neurosci. 10 (3): 1544–1554. https://doi.org/10.1021/
acschemneuro.8b00526.
176. Mossine, A.V., Tanzey, S.S., Brooks, A.F. etal. (2019). One-pot synthesis of high
molar activity 6-[
18
F]uoro-l-DOPA by Cu-mediated uorination of a BPin precursor.
Org. Biomol. Chem. 17 (38): 8701–8705. https://doi.org/10.1039/C9OB01758E.
177. Zarrad, F., Zlatopolskiy, B., Krapf, P. etal. (2017). A practical method for the prepara-
18
tion of
F-labeled aromatic amino acids from nucleophilic [18F]uoride and stannyl
precursors for electrophilic radiohalogenation. Molecules 22 (12): 2231. https://doi.
org/10.3390/molecules22122231.
178. Zlatopolskiy, B.D., Zischler, J., Schäfer, D. etal. (2018). Discovery of 7-[
18
F]uorotryptophan as a novel positron emission tomography (PET) probe for the visualization of tryptophan metabolism in vivo. J. Med. Chem. 61 (1): 189–206. https://doi.
org/10.1021/acs.jmedchem.7b01245.
179. Zhang, Z., Zhang, C., Lau, J. etal. (2016). One-step synthesis of 4-[
18
F]uorobenzyltriphenylphosphonium cation for imaging with positron emission tomography. J.
Labelled Compd. Radiopharm. 59 (11): 467–471. https://doi.org/10.1002/jlcr.3436.
180. Lien, V.T., Klaveness, J., and Olberg, D.E. (2018). One-step synthesis of [
18
F]cabozantinib for use in positron emission tomography imaging of c-met. J. Labelled Compd.
Radiopharm. 61 (1): 11–17. https://doi.org/10.1002/jlcr.3564.
181. Bernard-Gauthier, V., Mossine, A.V., Mahringer, A. etal. (2018). Identication of
18
[
F]TRACK, a uorine-18-labeled tropomyosin receptor kinase (Trk) inhibitor
for PET imaging. J. Med. Chem. 61 (4): 1737–1743. https://doi.org/10.1021/acs.
jmedchem.7b01607.
182. Reischl, G., Kienzle, G.J., and Machulla, H.-J. (2002). Electrochemical radiouorination: labeling of benzene with [
18
F]uoride by nucleophilic substitution. J. Radio-
anal. Nucl. Chem. 254 (2): 409–411. https://doi.org/10.1023/A:1021669126378.
183. Reischl, G., Kienzle, G.J., and Machulla, H.-J. (2003). Electrochemical radiouorination. Part 2. Anodic monouorination of substituted benzenes using [
18
F]uoride.
Appl. Radiat. Isot. 58 (6): 679–683. https://doi.org/10.1016/S0969-8043(03)00093-9.
184. Kienzle, G.J., Reischl, G., and Machulla, H.-J. (2005). Electrochemical radiouorination. 3. Direct labeling of phenylalanine derivatives with [
18
F]uoride after
Chapter 08: Fluorine-18 Radiochemistry 287
anodic oxidation. J. Labelled Compd. Radiopharm. 48 (4): 259–273. https://doi.
org/10.1002/jlcr.918.
185. Truong, T., Klimovica, K., and Daugulis, O. (2013). Copper-catalyzed, directing groupassisted uorination of arene and heteroarene C–H bonds. J. Am. Chem. Soc. 135
(25): 9342–9345. https://doi.org/10.1021/ja4047125.
186. Knowles, S.M. and Wu, A.M. (2012). Advances in immuno-positron emission
tomography: antibodies for molecular imaging in oncology. J. Clin. Oncol. 30 (31):
3884–3892. https://doi.org/10.1200/JCO.2012.42.4887.
187. Gagnon, M.K.J., Hausner, S.H., Marik, J. etal. (2009). High-throughput in vivo
screening of targeted molecular imaging agents. Proc. Natl. Acad. Sci. U. S. A. 106
(42): 17904–17909. https://doi.org/10.1073/pnas.0906925106.
188. Marik, J. and Sutclie, J.L. (2006). Click for PET: rapid preparation of [
18
F]uoropeptides using CuI catalyzed 1,3-dipolar cycloaddition. Tetrahedron Lett. 47 (37):
6681–6684. https://doi.org/10.1016/J.TETLET.2006.06.176.
189. Wang, M., Yuan, Y., and Liang, G. (2012). “Click Chemistry” for molecular imaging.
Curr. Mol. Imaging 1 (1): 87–95. https://doi.org/10.2174/2211555211201010087.
190. Kettenbach, K., Schieferstein, H., and Ross, T.L. (2014).
18
F-labeling
using click cycloadditions. Biomed Res. Int. 2014: 361329. https://doi.
org/10.1155/2014/361329.
191. Choi, J.Y. and Lee, B.C. (2010). Click reaction: an applicable radiolabeling method for
molecular imaging. Nucl. Med. Mol. Imaging 49 (4): 258–267. https://doi.org/10.1007/
s13139-015-0377-6.
192. Meyer, J.-P., Adumeau, P., Lewis, J.S. etal. (2016). Click chemistry and radiochemistry: the rst 10 years. Bioconjugate Chem. 27 (12): 2791–2807. https://doi.
org/10.1021/acs.bioconjchem.6b00561.
193. Donnelly, D.J., Smith, R.A., Morin, P. etal. (2018). Synthesis and biologic evaluation
of a novel
18
F-labeled adnectin as a PET radioligand for imaging PD-L1 expression. J.
Nucl. Med. 59 (3): 529–535. https://doi.org/10.2967/jnumed.117.199596.
194. Keliher, E.J., Reiner, T., Thurber, G.M. etal. (2012). Ecient
18
F-labeling of synthetic
exendin-4 analogues for imaging Beta cells. ChemistryOpen 1 (4): 177–183. https://
doi.org/10.1002/open.201200014.
195. Selvaraj, R., Liu, S., Hassink, M. etal. (2011). Tetrazine-trans-cyclooctene ligation
for the rapid construction of integrin αvβ3 targeted PET tracer based on a cyclic
RGD peptide. Bioorg. Med. Chem. Lett. 21 (17): 5011–5014. https://doi.org/10.1016/J.
BMCL. 2011. 0 4.116.
196. Namavari, M., Padilla De Jesus, O., Cheng, Z. etal. (2008). Direct site-specic
radiolabeling of an abody protein with 4-[
18
F]uorobenzaldehyde via oxime
chemistry. Mol. Imaging Biol. 10 (4): 177–181. https://doi.org/10.1007/s11307008- 0142-7.
197. Glaser, M., Iveson, P., Hoppmann, S. etal. (2013). Three methods for
18
F
labeling of the HER2-binding abody molecule Z(HER2:2891) including preclinical assessment. J. Nucl. Med. 54 (11): 1981–1988. https://doi.org/10.2967/
jnumed.113.122465.
288 Handbook of Radiopharmaceuticals
198. Dirksen, A. and Dawson, P.E. (2008). Rapid oxime and hydrazone ligations with aromatic aldehydes for biomolecular labeling. Bioconjugate Chem. 19 (12): 2543–2548.
https://doi.org/10.1021/bc800310p.
199. Cai, W., Zhang, X., Wu, Y. etal. (2006). A thiol-reactive
18
F-labeling agent, N-[2-(418F-uorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based
tracer for PET imaging of alpha v beta 3 integrin expression. J. Nucl. Med. 47 (7):
1172–1180. https://jnm.snmjournals.org/content/47/7/1172.long.
200. Li, Z., Cai, H., Hassink, M. etal. (2010). Tetrazine–trans-cyclooctene ligation for the
rapid construction of 18F labeled probes. Chem. Commun. 46 (42): 8043. https://doi.
org/10.1039/c0cc03078c.
201. Meyer, J.-P., Houghton, J.L., Kozlowski, P. etal. (2016).
18
F-based pretargeted PET
imaging based on bioorthogonal diels−alder click chemistry. Bioconjugate Chem. 27:
298–301. https://doi.org/10.1021/acs.bioconjchem.5b00504.
202. Schirrmacher, R., Bradtmöller, G., Schirrmacher, E. etal. (2006).
18
F-labeling of peptides by means of an organosilicon-based uoride acceptor. Angew. Chem. Int. Ed.
45 (36): 6047–6050. https://doi.org/10.1002/anie.200600795.
203. Li, Y., Ting, R., Harwig, C.W. etal. (2011). Towards kit-like
18
F-labeling of Marimastat,
a noncovalent inhibitor drug for in vivo PET imaging cancer associated matrix metalloproteases. Medchemcomm 2 (10): 942. https://doi.org/10.1039/c1md00117e.
204. McBride, W.J., Sharkey, R.M., Karacay, H. etal. (2009). A novel method of
18
F
radiolabeling for PET. J. Nucl. Med. 50 (6): 991–998. https://doi.org/10.2967/
jnumed.108.060418.
205. Inkster, J.A.H., Liu, K., Ait-Mohand, S. etal. (2012). Sulfonyl uoride-based
prosthetic compounds as potential
18
F labelling agents. Chem. Eur. J. 18 (35):
11079–11087. https://doi.org/10.1002/chem.201103450.
206. Wright, J. S., Kaur, T., Preshlock, S. etal. (2020). Copper-mediated late-stage radiouorination: ve years of impact on preclinical and clinical PET imaging. Clin. Transl
Imaging 8 (3): 167–206. https://doi.org/10.1007/s40336-020-00368-y.
Chapter 08: Fluorine-18 Radiochemistry 289
Chapter 9
Labeling
withGallium-68
Benjamin P. Burke and Stephen J. Archibald
Positron Emission Tomography Research Centre, Department of
Biomedical Sciences, Faculty of Health Sciences, University of
Hull, Hull, HU6 7RX, UK
9.1 INTRODUCTION
Gallium-68 has seen the largest growth in nuclear medicine usage of any isotope over the
past 10 years. This is due to a combination of factors: the rise of PET/CT, the availability
of the isotope (driven by the
peptidic targeted agents, facile labeling processes, and the recognition of the potential
in the theranostics market. Obtaining accurate
scan numbers is challenging, but based on generator sales, it can be estimated that over
200 000 scans are carried out annually worldwide (using the conservative gure of 100
scans per generator sold). Licensed
statin receptors (SSTRs) are now considered the clinical standard for imaging neuroendocrine tumors (NETs), and the prostate-specic membrane antigen (PSMA) ligands in
development may shortly follow suit for prostate tumors. The likely future success of
68
Ga is built on the theranostic combination with
transition into routine clinical practice over the coming years. The Society for Nuclear
Medicine and Molecular Imaging (SNMMI) annual meeting has selected images with
gallium-68 radiotracers as the “Image of the Year” for four out of the ve years from 2015
to 2019, giving an accurate indication of the impact and level of interest in this isotope.
The short half-life (t
positron emission (88%) of
energy is higher (max 1.9 MeV, mean 0.89 MeV) than for uorine-18 (max 0.63 MeV, mean
0.25 MeV), the dierence in image quality is marginal when using modern clinical PET
68
Ge/68Ga generator), the development of clinically desirable
68
Ga positron emission tomography (PET)
68
Ga-radiopharmaceuticals for targeting the somato-
177
Lu, with more agents expected to
=68 minutes) and high percentage of radioactive decay by
1/2
68
Ga are well suited to PET imaging, and whilst the positron
Handbook of Radiopharmaceuticals: Methodology and Applications, Second Edition.
Edited by Michael R. Kilbourn and Peter J.H. Scott.
© 2021 John Wiley & Sons Ltd. Published 2021 by John Wiley & Sons Ltd.
scanners[1–3]. The long-lived parent isotope, 68Ge (t
=271 days), is generally produced
1/2
on an accelerator with a natural gallium or gallium-containing target, prior to separation
and incorporation onto a stationary phase for production of the
The use of
68
Ge/68Ga generators (which can produce radioisotope for up to 12 months)
68
Ge/68Ga generator.
allows for worldwide distribution and widespread use without the need for a cyclotron.
When compared with routine clinically used cyclotron produced isotopes (
use of a
68
Ga generator oers some advantages. PET centers that do not have a cyclotron
11C/18
F), the
and rely on delivery of uorine-18 tracers can introduce gallium-68 tracer production
by a relatively simple modication of an existing technetium radiopharmacy suite[4]. If
required to meet capacity demands, larger amounts of gallium-68 can be produced in a
standard biomedical cyclotron using a solid target. Recently, production methods have
been extended to solution targets, to allow cyclotron production of the isotope at sites
that are not equipped to handle solid targetry. Overall, there are a number of models for
the production of gallium-68 radiopharmaceuticals, adding to its potential utility.
The rst major successes in this eld were the
signicantly increased diagnostic capability compared to the established
68
Ga-octreotide derivatives, which oer
111
In derivatives
used in clinical single-photon emission computed tomography (SPECT) imaging. This
stimulated an increase in research activity due to the general applicability of peptide conjugates to many biological targets and diseases. Coupling this with the development of
protocols improving the chemistry for radiolabeling to simplify tracer synthesis further
adds to the future potential in this area. Cheaper and simpler protocols to access the
tracers will drive down the at-patient costs and increase widespread availability, ensuring
a bright future for gallium-68 PET imaging.
There are two options used for 68Ga production: by decay of 68Ge (t
erator, or from
focus on the development of easy-to-use cGMP
majority of clinical
68
duced
Ga is a more recent development, driven by increasing demand for the isotope
placing a strain on generator production capacity and the limit on the total amount of
68
Ga produced from each generator (some high-demand sites now have racks of genera-
tors in use at any one time).
The simplest way to produce
not require a change in infrastructure and is compatible with most cyclotron sites[5–8].
An amount of
in around an hour (bombardment and separation). Standard synthesis units can be used
for both processing of the feed from the cyclotron and synthesis of the radiotracer. There
is potential corrosion from the use of concentrated acid, and care needs to be taken
because the hot cell environment can contain radioactive gaseous waste, as
pounds are a byproduct.
292 Handbook of Radiopharmaceuticals
68
Zn using a cyclotron. Over the past 20 years, there has been signicant
68
Ga imaging uses isotope produced by this method. Cyclotron-pro-
68
Ga equivalent to the yield from one or two generators can be produced
=271 days) in a gen-
1/2
68
Ge/68Ga generators (vide infra); the
68
Ga on a cyclotron is by using a liquid target, as this does
13
N com-
68
Ga can also be produced on a cyclotron using a solid target [9–11], with up to a
10-fold increase in the amount of
68
Ga produced in comparison with a generator. Irra-
diation times and separation chemistry are similar to using a liquid target, but with the
increased practical complexities of handling the solid target. However, if a high-demand
center is equipped to handle these challenges, the reward in terms of cost per dose will
make this method viable. As with any cyclotron production, especially with metals, production of unwanted radiometal byproducts must be considered; with
of the main contaminants,
of enriched
68
Zn target material[5, 9]. In addition, there are complexity considerations
66
Ga and 67Ga, is inversely proportional to the isotopic purity
68
Ga, the amount
related to post-production isotope purication, which are not present with generator-
produced
68
Ga.
68
Ge/68Ga generators provide isotope without the need for a cyclotron and can be
incorporated into existing radiopharmacies with only minor facility modication. All
modern generators can provide ionic
year. Whilst there may be some specic centers in which cyclotron-produced
68
Ga in hydrochloric acid every few hours for up to a
68
Ga oers
the best solution for routine clinical imaging (dependent on facility capability and clinical
demand), the majority of centers will likely continue to use generator-produced isotope
in the short term.
For radiolabeling, the characteristics of an ideal
68
Ga generator are:
• Low elution volume (high activity per volume)
• Low [H]
+
concentration (compatibility with direct kit synthesis or pre-purication)
• Low level of germanium-68 breakthrough
• Consistency of elution characteristics over the generator lifetime
• Low amount of metal ion contamination
• High isotope yield
• Simplicity of use
• Compatibility with licensed radiopharmaceuticals
Currently, ve main
Table9.1). The most widely used generator–GalliaPharm, produced by Eckert &
Ziegler (EZAG)–received marketing authorization in 2014. This was followed by the
Galli Ad–produced by IRE ELiT–which received marketing authorization in 2018. The
maximum generator size available is currently 50 mCi (1.85 GBq), although larger genera-
tors are currently in development. The level of breakthrough of
major limiting factors in gaining marketing authorization, so generators using TiO
columns are the only ones currently licensed. Ideally,
with the capability to use the generator eluate directly (for the lifetime of the gener-
ator) with a single-vial lyophilized kit to rapidly produce a radiotracer with high molar
activity (i.e. both pre-purication and radiosynthesis using a synthesis module would
become obsolete). To achieve this, the generator used must elute
weak acid solution to be easily buered; this eluate must maintain acceptable amounts
68
Ge/68Ga generator products are being used globally (see
68
Ge has been one of the
68
Ga will ultimately emulate
68
Ga in a low volume of
-based
2
99m
Tc,
Chapter 9: Labeling withGallium-68 293
294 Handbook of Radiopharmaceuticals